Talley NJ, Moore MG, Sprogis A, Katelaris P. Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care.
Med J Aust 2002;
177:423-7. [PMID:
12381251 DOI:
10.5694/j.1326-5377.2002.tb04882.x]
[Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2001] [Accepted: 06/27/2002] [Indexed: 12/13/2022]
Abstract
OBJECTIVES
To investigate whether pantoprazole (20 mg/d) produces significantly greater symptom control than ranitidine (300 mg/d) in patients with gastro-oesophageal reflux disease (GORD).
DESIGN
Multicentre, randomised, double-blind, parallel-group comparison.
SETTING
76 general practices in north-west Sydney and Newcastle, New South Wales (Australia), from 19 January 1999 to 22 September 2000.
PATIENTS
307 patients aged 18 years or over presenting with symptomatic GORD.
INTERVENTIONS
Pantoprazole (20 mg once daily) or ranitidine (150 mg twice daily).
MAIN OUTCOME MEASURES
Patient-assessed frequency and severity of heartburn using the Gastrointestinal Symptom Rating Scale (GSRS) and a patient heartburn diary.
RESULTS
Pantoprazole was associated with significantly higher rates of complete control of GORD symptoms than ranitidine at four weeks (40% v 19%; P < 0.001), eight weeks (55% v 33%; P < 0.001), six months (71% v 56%; P = 0.007) and 12 months (77% v 59%; P = 0.001).
CONCLUSIONS
Low-dose pantoprazole is an effective alternative to standard-dose ranitidine for initial and maintenance treatment of patients with symptomatic GORD.
Collapse